The future of obesity care is at a crossroads, and the path forward hinges on a critical decision: how we expand and adapt our chronic condition management plans to support effective obesity treatment. The introduction of GLP-1s has revolutionized weight loss, but their true potential can only be unlocked with the right support systems in place. In my opinion, the current Chronic Condition Management Plans (CCMPs) under Medicare are not adequately equipped to handle the complexities of obesity care. The model, while effective for some conditions, falls short in addressing the unique needs of patients seeking obesity treatment. One of the most pressing issues is the rigid structure of the CCMP framework. The current cap of five allied health services per year is simply not enough for patients in the early stages of treatment, where more frequent interactions are crucial for managing side effects, supporting behavioral change, and optimizing adherence. This limitation disproportionately affects rural and regional patients, who often face a higher burden of disease and limited access to in-person GP consultations. What makes this particularly fascinating is the potential for asynchronous care models, such as messaging and group-based sessions, to bridge the gap in access. These approaches can deliver care more efficiently, reduce costs, and improve access, especially in remote areas. However, the CCMP currently excludes these flexible models, leaving patients with high out-of-pocket costs and limited support. From my perspective, the solution lies in targeted reforms to the CCMP. We need to expand the range of supported service delivery models, increase flexibility to the current cap, and broaden the range of eligible providers to include nurses and pharmacists. These changes would better align the CCMP with modern, scalable models of care, improving patient outcomes while supporting more efficient use of health system resources. The implications of these reforms are far-reaching. By optimizing access to wraparound care, we can maximize the value of public investment in emerging therapies like GLP-1s. This, in turn, can lead to meaningful gains in productivity and equity, while reducing overall healthcare expenditure. What many people don't realize is that the current CCMP model does not reflect the modern multidisciplinary care that is essential for effective obesity treatment. Pharmacists and nurses, outside of a specific practice, are excluded from eligible providers, despite their critical role in medication management, patient education, and early-stage support. This limitation creates a risk that otherwise effective therapies are underutilized or discontinued prematurely, reducing their overall clinical and economic value. In conclusion, the future of obesity care depends on our ability to adapt and expand our chronic condition management plans. By embracing flexible service delivery models, increasing access, and aligning with contemporary care models, we can unlock the true potential of GLP-1s and other emerging therapies. This, in turn, can lead to improved patient outcomes, reduced healthcare costs, and a more equitable healthcare system for all.
